Investigational Drug Details
| Drug ID: | D294 |
| Drug Name: | Quinidine |
| Synonyms: | (+)-quinidine; (8R,9S)-Quinidine; (R)-(6-Methoxyquinolin-4-yl)((3S,4R,7S)-3-vinylquinuclidin-7-yl)methanol; (S)-(6-Methoxy-quinolin-4-yl)-((2R,5R)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol; (S)-(6-Methoxyquinolin-4-yl)((2R,5R)-5-vinylquinuclidin-2-yl)methanol; 6-methoxy-α-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol; beta-Quinine; CIN-QUIN; Conchinin; Conquinine; Pitayine; α-(6-methoxy-4-quinolyl)-5-vinyl-2-quinuclidinemethanol; β-quinine |
| Type: | Chemical drug |
| DrugBank ID: | DB00908 |
| DrugBank Description: | An optical isomer of , extracted from the bark of the Cinchona tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular action potential, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission. |
| PubChem ID: | 441074 |
| CasNo: | 56-54-2 |
| Repositioning for NAFLD: | Yes |
| SMILES: | [C@H](O)(c1c2c(ccc(c2)OC)ncc1)[C@@H]1N2C[C@@H]([C@H](C1)CC2)C=C |
| Structure: |
|
| InChiKey: | LOUPRKONTZGTKE-LHHVKLHASA-N |
| Molecular Weight: | 324.424 |
| DrugBank Targets: | Sodium channel protein type 5 subunit alpha inhibitor; Potassium channel subfamily K member 1 inhibitor; Potassium channel subfamily K member 6 inhibitor; Potassium voltage-gated channel subfamily H member 2 inhibitor; Alpha-1A adrenergic receptor antagon |
| DrugBank MoA: | Quinidine acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers. Quinidine may also act on the slow inward calcium current (ICa), the rapid (IKr) and slow (IKs) components of the delayed potassium rectifier current, the inward potassium rectifier current (IKI), the ATP-sensitive potassium channel (IKATP) and Ito. |
| DrugBank Pharmacology: | Quinidine, a hydantoin anticonvulsant, is used alone or with phenobarbital or other anticonvulsants to manage tonic-clonic seizures, psychomotor seizures, neuropathic pain syndromes including diabetic neuropathy, digitalis-induced cardiac arrhythmias, and cardiac arrhythmias associated with QT-interval prolongation. |
| DrugBank Indication: | For the treatment of ventricular pre-excitation and cardiac dysrhythmias |
| Targets: | KCNH2 inhibitor |
| Therapeutic Category: | Antiadrenergic drug; Antiarrhythmic; Antiprotozoal drug; Cholinergic drug |
| Clinical Trial Progress: | Phase 2 completed (NCT03421431: Non-alcoholic fatty liver disease is a chronic hepatic disease that can progress to non-alcoholic steatohepatitis (NASH), which is associated with an increased risk of cirrhosis and liver cancer. Results from this phase II study support continued development of EDP-305, an oral farnesoid X receptor agonist, for the treatment of patients with NASH.) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0309 | NCT03610945 | Phase 1 | Completed | No Results Available | July 19, 2018 | December 5, 2018 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|